Physician profile
David Ware
NPI 1760445084
$3,718.79
in general payments reported to CMS, 2019-2025
27 companies · $15.85 in 2025
The $15.85 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $824 · 2020: $632 · 2021: $764 · 2022: $1,150 · 2023: $315 · 2024: $16.38 · 2025: $15.85.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $348.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $347.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $811.87 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $464.40 | 2021-2023 | Vraylar |
| Sanofi-Aventis U.S. LLC | $376.40 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $268.66 | 2019-2023 | Steglatro |
| Amgen INC. | $252.29 | 2019-2023 | Prolia, Evenity, Repatha |
| Pfizer INC. | $239.67 | 2019-2023 | |
| Astrazeneca Pharmaceuticals Lp | $236.83 | 2019-2024 | Airsupra, Fasenra |
| Lilly USA, LLC | $163.66 | 2020-2023 | Mounjaro |
| Amarin Pharma, INC. | $132.52 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $118.65 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $100.43 | 2019-2023 | Livalo, Seglentis |
| Takeda Pharmaceuticals U.S.A., INC. | $96.23 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $79.61 | 2019 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $72.03 | 2022 | |
| Abbott Laboratories | $50.82 | 2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $48.98 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $33.50 | 2022 | |
| Nestle Healthcare Nutrition INC. | $29.13 | 2021-2022 | |
| Mannkind Corporation | $22.63 | 2022 | |
| Exact Sciences Corporation | $18.95 | 2023 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $16.86 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $15.71 | 2023 | Eliquis |
| Glaxosmithkline, LLC. | $15.35 | 2019 | |
| Allergan, INC. | $15.29 | 2020 | |
| Astellas Pharma US INC | $13.43 | 2023 | Myrbetriq |
| Gilead Sciences, INC. | $13.08 | 2020 | |
| Esperion Therapeutics, INC. | $11.81 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Ware listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.